Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Payables (2021 - 2025)

Biote has reported Payables over the past 5 years, most recently at $6.8 million for Q4 2025.

  • Quarterly results put Payables at $6.8 million for Q4 2025, up 17.43% from a year ago — trailing twelve months through Dec 2025 was $6.8 million (up 17.43% YoY), and the annual figure for FY2025 was $6.8 million, up 17.43%.
  • Payables for Q4 2025 was $6.8 million at Biote, up from $4.4 million in the prior quarter.
  • Over the last five years, Payables for BTMD hit a ceiling of $9.2 million in Q2 2022 and a floor of $558.0 in Q1 2021.
  • Median Payables over the past 5 years was $4.4 million (2024), compared with a mean of $4.8 million.
  • Biggest five-year swings in Payables: skyrocketed 67215.95% in 2022 and later plummeted 33.32% in 2025.
  • Biote's Payables stood at $4.3 million in 2021, then fell by 5.45% to $4.1 million in 2022, then grew by 1.05% to $4.2 million in 2023, then surged by 39.9% to $5.8 million in 2024, then rose by 17.43% to $6.8 million in 2025.
  • The last three reported values for Payables were $6.8 million (Q4 2025), $4.4 million (Q3 2025), and $3.9 million (Q2 2025) per Business Quant data.